Previous Close | 62.63 |
Open | 64.13 |
Bid | 64.60 x 1300 |
Ask | 64.57 x 800 |
Day's Range | 63.17 - 65.77 |
52 Week Range | 46.93 - 93.80 |
Volume | |
Avg. Volume | 152,645 |
Market Cap | 1.57B |
Beta (5Y Monthly) | 1.11 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.66 |
Earnings Date | Nov 07, 2022 - Nov 11, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 91.80 |
Subscribe to Yahoo Finance Plus to view Fair Value for ESTA
Establishment Labs Holdings Inc. (ESTA) delivered earnings and revenue surprises of -114.29% and 8.97%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
SANTA BARBARA, Calif., August 08, 2022--Establishment Labs Holdings Inc. (Nasdaq: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced its financial results for the second quarter ended June 30, 2022.
SANTA BARBARA, Calif., August 03, 2022--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced it has completed enrollment in the Motiva US IDE clinical study. The final surgery in the primary reconstruction cohort was completed at Northwestern Memorial Hospital. The Augmentation cohort, which finished enrollment in August of 2019, will complete i